Document Detail


Relationship of serum imatinib trough level and response in CML patients: long term follow-up.
MedLine Citation:
PMID:  20688395     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
One hundred and three patients with Philadelphia chromosome or BCR-ABL positive chronic myeloid leukemia (CML) in chronic phase who were on oral imatinib were included in this study. The study aimed to assess the relationship between imatinib trough serum levels and clinical outcome (as determined by molecular response) in Jordanian CML patients who have been on imatinib therapy for at least 12 months. The mean trough imatinib serum level in the group with complete molecular response (CMR) was 2891±856 ng/ml, the group with major molecular response (MMR) was 2337±434 ng/ml, the group with complete cytogenetic response (CCyR) was 1817±563 ng/ml, and the group without CCyR was 1723±673 ng/ml. A receiver operating characteristic (ROC) curve was constructed after dividing patient sample into two groups, those with MMR or better and those without MMR, in order to estimate a threshold for imatinib level that correlates with a favorable response (the former group), and analysis yielded a value of 2158 ng/ml.
Authors:
Abdalla Awidi; Ayed O Ayed; Nazzal Bsoul; Ahmad Magablah; Razan Mefleh; Mohammad Dweiri; Mohammad Ramahi; Eyad Arafat; Mohammad Bishtawi; Lena Marie
Related Documents :
10539885 - Long-term treatment of refractory thrombocytopenia in a patient with wiskott-aldrich sy...
2891995 - Difluoromethylornithine for arseno-resistant trypanosoma brucei gambiense sleeping sick...
23725485 - Proximal metatarsal osteotomy for hallux valgus: an audit of radiologic outcome after s...
23186285 - Early results of a european multicentre experience with a new self-anchoring adjustable...
7168905 - Post treatment behaviour of cervical intraepithelial neoplasia - grade iii.
1595775 - Charting of daily weight pattern reinforces maintenance of weight reduction in moderate...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-04
Journal Detail:
Title:  Leukemia research     Volume:  34     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-08     Completed Date:  2010-12-21     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  1573-5     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Affiliation:
Department of Hematology, Jordan University, Amman, Jordan. aawidi@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents / administration & dosage,  pharmacokinetics*
Child
Female
Follow-Up Studies
Humans
Jordan
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*,  mortality*
Male
Middle Aged
Piperazines / administration & dosage,  pharmacokinetics*
Pyrimidines / administration & dosage,  pharmacokinetics*
ROC Curve
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients...
Next Document:  Effects of Cd- and Zn-enriched sewage sludge on soil bacterial and fungal communities.